Rapivab

Chemical Nameperamivir
Dosage FormInjection (intravenous; 200mg/20mL, 10mg/mL)
Drug ClassAntivirals
SystemRespiratory
CompanyBioCryst Pharmaceuticals
Approval Year2014

Indication

  • For the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.
Last updated on 7/13/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rapivab (peramivir) Prescribing Information.2021BioCryst Pharmaceuticals, Inc., Durham, NC
Document TitleYearSource
Australian public assessment report for peramivir. 2019Australian Government: Department of Health